Skip to main
TMO

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 61%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to experience revenue growth across its segments, with lab products and services (LPBS) anticipated to expand at a compound annual growth rate (CAGR) of 5.4% over the next three years, despite a prior rate of 16.9% from 2019 to 2024. The company's analytical instruments segment is expected to grow at a more moderate CAGR of 2.5%, reflecting a shift in market dynamics while still contributing positively to the overall performance. Additionally, an 8.5% CAGR in adjusted earnings per share (EPS) over the next four years indicates a robust financial outlook driven by growth initiatives and strategic positioning within the clinical research organization (CRO) market.

Bears say

Thermo Fisher Scientific has experienced a significant decline in its adjusted EBIT margin, which fell by approximately 830 basis points to 22.6% from 2021 to 2024, driven by a sharp reduction in adjusted gross margin that decreased by around 940 basis points to 42.2%. This decline has placed the company's margins below pre-pandemic levels, with the adjusted gross margin currently about 420 basis points lower than the 46.4% recorded in 2019. Additionally, despite recent claims of improved biotech customer sentiment, early-stage funding in 2025 is lagging, with a 45% year-over-year decrease in capital raised, raising concerns about future revenue growth.

TMO has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 61% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 18 analysts, TMO has a Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $631, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $631, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.